We're Holding Rocket Lab Despite 356% Rally

Rocket Lab posted its first $200 million revenue quarter, with Q1 fiscal 2026 revenue of $200.35 million beating consensus by 5.77% and EPS of -$0.07 beating by 11.05%, while backlog reached a record $2.2 billion. However, the stock is already up 356.85% over 12 months and trades at $122.39 versus a 24/7 Wall St. target of $113.26, implying 7.46% downside and a HOLD rating. The article highlights upside from Neutron and Golden Dome awards, but valuation, dilution, and ongoing GAAP losses keep the stance cautious.

Analysis

The market is now treating RKLB less like an early-stage launch vendor and more like a scarce, strategic defense asset with an option on becoming a vertically integrated medium-lift prime. That re-rating creates a self-reinforcing dynamic: every credible Neutron milestone can compress the cost of capital, which in turn improves the odds of financing the next leg of fixed-asset buildout without a catastrophic equity overhang. The problem is that the stock is already discounting a meaningful fraction of that path, so the marginal catalyst needs to be execution, not just narrative.

The near-term winner is the supply chain and contractor ecosystem tied to propulsion, avionics, and launch infrastructure, because Rocket Lab’s scaling plan is likely to front-load orders before revenue fully catches up. That tends to help niche aerospace suppliers and selected defense electronics names before it helps RKLB shareholders, because the capex and inventory cycle comes first and the operating leverage comes later. Competitively, the bigger second-order risk is not SpaceX-style direct launch competition but customer waiting behavior: if agencies believe Neutron slips, they may keep multi-year awards fragmented across incumbents, limiting Rocket Lab’s ability to convert backlog into pricing power.

The consensus appears to be underestimating dilution as a long-duration drag rather than a one-time financing event. Even if the company executes, repeated capital raises or stock comp at elevated share prices can mute per-share upside for 12-24 months, which is why the stock can stagnate even with strong top-line growth. Conversely, if Neutron hits schedule and early missions are clean, the stock can gap higher quickly because the market will start capitalizing a defense platform, not a launch service business.

This is a classic “good company, crowded stock” setup: fundamentals can improve while forward returns compress. The key inflection is whether management converts current enthusiasm into a credible path to gross margin expansion and lower external funding dependence by late 2026. Until then, the asymmetry favors tactical trading over a blanket long.

Key Decisions for Investors

• Trim or hedge existing RKLB longs into strength over the next 2-6 weeks; use a 3-6 month collar if you need to keep exposure, because the stock is already pricing in a favorable 2026-2027 execution path.
• For event-driven upside, buy RKLB call spreads dated 6-9 months out only on post-rally consolidation; target a move tied to Neutron milestones, with defined premium risk and limited downside if schedule slips.
• Pair trade: long a basket of defense-electronics / aerospace suppliers that benefit from Rocket Lab capex and launch buildup, short RKLB against it, to isolate execution risk while capturing the supplier-demand tailwind.
• Avoid initiating fresh unhedged longs until there is evidence that backlog is converting into margin expansion and dilution is slowing; otherwise the per-share compounding math remains unfavorable despite strong revenue growth.
• Set a tactical short trigger on any delay signal for Neutron or financing commentary; a 1-2 quarter slip should force multiple compression quickly because the current valuation leaves little room for execution disappointment.